支气管扩张病例应用23价肺炎球菌多糖疫苗的临床观察

Clinical observation on the application of 23-valent pneumococcus polysaccharide vaccine in bronchiectatic patients

目的:探讨23价肺炎球菌多糖疫苗在支气管扩张患者的临床意义。方法:通过对28例支气管扩张患者注射23价肺炎球菌多糖疫苗后1年内肺部感染发生率及再发肺部感染的相距时间与对照组进行对比回顾性分析。结果:28例支气管扩张病例中在注射23价肺炎球菌多糖疫苗后1年内5例(17.85%),对照组35例支气管扩张病例1年内16例(45.70%)再发肺部感染,两者比较有显著性差异(P<0.05)。治疗组再发肺部感染相距时间为(168±92)d;对照组再发肺部感染相距时间为(157±94)d;两者比较无显著性差异(P>0.05)。结论:23价肺炎球菌多糖疫苗能有效地减少支气管扩张患者肺部感染复发率,是临床佐治支气管扩张患者的一个有效方法,值得临床推广。

Objective. To investigate clinical significance in the application of 23 - valent pneumococcus polysaccharide vaccine in bronchiectatic patients. Methods： A retrospective analysis was made on the incidence rate of pulmonary infection and the interval of recurrent pulmonary infection through a clinical study of 28 patients with bronchiectasis one year after injection of 23 - valent pneumococcus polysaccharide vaccine. Results： Of the 28 cases of bronchiectatic patients who were injected with 23 - valent pneumococcus polysaccharide vaccine, 5 （accounting for 17.85 % ） recurred in 1 year with pulmonary infection, while for the control group, 16 out of 35 cases recurred also in 1 year with the same infection （accounting for 45.7% ）. Significant difference could be ,seen when a comparian was made between the 2 （P〈0.05）. Recurrent interval for the treatment group, was 168 ±92 days, while that for the control group was 157 ± 94 days. No significant difference could be ,seen between the 2 when a comparison was made （P〉0.05）. Conclusion： 23 - valent pneumococcus polysaccharide vaccine could effectively reduce recurrent rate of pulmonary infection in bronchiectatic patients. Therefore, it might be an effective adjuvant for the treatment of bronchiectasis, which is worth extending its clinical application.